Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013

Similar documents
leading the way in research & development

Comments from the FDA Working Group on SUBGROUP ANALYSES. Estelle Russek-Cohen, Ph.D. U.S. Food and Drug Administration Center for Biologics

"Stratification biomarkers in personalised medicine"

Molecular Diagnostics

PLTW Biomedical Science Medical Interventions Course Outline

FDA Perspectives on Biomarkers. Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

Nanotechnology and Advanced Materials for more effective Healthcare

Report from the Paediatric Committee on its first anniversary

Rare Diseases: Challenges and Opportunities NIH Perspective

Terminology for personalized medicine

BIOMEDICAL RESEARCH CENTRES

HD Regulatory Science Consortium (HD-RSC) A consortium aimed at accelerating treatments for Huntington s disease

Leveraging an Academic-Industry Partnership for Commercial Success

Development Stage of Therapeutic Vaccines: The Regulator s View

MOSAIQUES DIAGNOSTICS

Preanalytical Variables in Blood Collection: Impact on Precision Medicine

ict Multi-Year Grants Funding Opportunity

WHILE A SMALL NUMBER OF PEOPLE ARE SUFFERING FROM A SINGLE RARE DISEASE, 350 MILLION PEOPLE WORLDWIDE ARE SUFFERING FROM RARE DISEASES.

ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3

SMEs in IMI2 Calls for Proposals

CDRH Device Approval

REIMAGINING DRUG DEVELOPMENT:

Webinar IMI2 Call 14 Opportunities for SMEs

EU support for Health Research from FP6 to FP7

A unique Collaborative Model for the Discovery of New Therapeutic Approaches

Use of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA

WORK PROGRAMME 2007 COOPERATION THEME 1 HEALTH. (European Commission C(2007)560 of )

Office for Human Subject Protection. University of Rochester

Presentation to the Committee on Accelerating Rare Disease Research and Orphan Product Development

Guide for National Scientific and Regulatory Advice

Biomarkers: Physiological & Laboratory Markers of Drug Effect

First Annual Biomarker Symposium Quest Diagnostics Clinical Trials

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

MEDICINES CONTROL COUNCIL

Personalized. Health in Canada

Malaria Research Capability Strengthening in Africa

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

WITA/GWU TRADE SEMINAR September 29, 2016 Washington D.C. RICHARD KJELDGAARD INTELLECTUAL PROPERTY AND TRADE CONSULTANT

November 5 th, 2013 FOCUS 2014 COMPETITION

WORK PROGRAMME 2008 COOPERATION THEME 1 HEALTH. (European Commission C(2007)5765 of 29 November 2007)

BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

GMO Technology Conference

NHS ENGLAND BOARD PAPER

IBBL: Introduction to Biobanks and their services

Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)

Pharmabiotics: a Regulatory Hurdle in Europe

EU Regulation Review: challenges and opportunities for industry

INTELLIGENT ANTIBODY DISCOVERY FROM HUMANS AND OTHER ANIMALS. Guy Cavet

Market Research at the NCBiotech Library

CRO partner in Rx/CDx Co-Development

Reflection paper on co-development of pharmacogenomic biomarkers and Assays in the context of drug development

Individualised medicine: regulatory challenges

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Neue Technologien für die patientennahe personalisierte Diagnostik

The Revised SmPC Guideline

Clinical Research Service Provider Information Form

CENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS

Introduction to Quantitative Imaging as a Biomarker in Clinical Trials

BIOMARKERS AND DRUG DEVELOPMENT: REGULATORY PERSPECTIVE

Outline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD

Speed your time to market with FDA s expedited programs

Defining Clinical Benefit in Clinical Trials: FDA Perspective

Biomarkers, Early Prediction of Vaccine Efficacy and Safety

FDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.

FINAL DOCUMENT. Global Harmonization Task Force. Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts

Research and development case study. Human health research

Human Research Protection Program Guidance for Human Research Determination

Envigo Corporate & Industry Overview. Rutgers University

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

The era of biological medicines

Question 1: Better codification and classification of RD Yes, we agree. Question 2: Establishment of an inventory of RD Yes I agree.

Explanatory note on general fees payable to the European Medicines Agency

Update on the IVDR. Sue Spencer

Roche, Roche Molecular Diagnostics and more

Q Presentation , Oslo

FDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010

Medical Device Development Tools. Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff

Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi

LOINC in Regulated Clinical Research a Lab LOINC Steeringg Committee Meeting 08 June 2017

Translational Research

Rare diseases in the 7th EU Framework Programme for Research and Technological Development

FDA Perspective on the Preclinical Development of Cancer Vaccines

Designing a Disease-Specific Master Protocol

The Innovative Medicines Initiative: Building new models of collaborative research across Europe

Centralised Procedure and Scientific Advice: an Overview

FCT PhD Programme Medicines and Pharmaceutical Innovation (i3du)

BBMRI.NL A story of Sharing Eline Slagboom Molecular Epidemiology, Leiden University Medical Center Brussel 20 Juni 2017

COPE. FAQs CORPORATE ONCOLOGY PROGRAM FOR EMPLOYEES

EARLY DIAGNOSIS OF BRAIN DISEASES via liquid biopsy, based on mirna patterns in microglial microvesicles

Partnering & Networks

Understanding the impact of publications in specialist areas: focus on orphan drugs

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

Delivering on the promise: the clinical application of new diagnoses and treatments for RD K A T E B U S H B Y N E W C A S T L E U N I V E R S I T Y

Utilizing Innovative Statistical Methods. Discussion Guide

Joint Technology Initiative: Innovative Medicine Initiative

BIOCRATES Life Sciences AG Short Company Presentation

Launching drug product in Europe Q&A

Transcription:

Forthcoming Calls for Proposals (10/11) Barcelona 28 June 2013

Indicative list Proposed topic /11 /11 /11 Identification and validation of innovative clinical endpoints for Osteoarthritis European genotype-phenotype repository (EURIPIDES) Correlates of Protection (influenza vaccines) European Platform for Proof-of Concept Trials for Alzheimer Disease (EPOC) Blood-based Biomarker assays for personalized tumor therapy: the value of circulating tumor cells, tumor DNA, and mirna Zoonoses Anticipation and Preparedness Initiative Identification and clinical validation of new targets European clinical research network for children and adolescents with diabetes and endocrine disorders Consistency of approach for vaccines batch release ND4BB: mixed infections, gram-negative/positive, 1-2 clinical studies ND4BB: clinical study, paediatric Developing Drug-Drug Combinations 2

Identification and validation of innovative clinical endpoints for Osteoarthritis Enhance the ability to prospectively identify specific OA patient subsets and enable the ability to conduct focused hypothesis-driven clinical trials European genotype-phenotype repository (EURIPIDES) Generate controlled access database (data safe haven) for qualified entities (genotype, phenotype, health records) by linking available data (both omic and linked phenotypic) from pharma, government, academics, etc. Correlates of Protection (influenza vaccines) Improve and standardise the immunological assays to better evaluate the new and improved influenza vaccines (serological assays and clinically relevant surrogate markers of protection) European Platform for Proof-of Concept Trials for Alzheimer Disease (EPOC) We propose to build a European Platform to facilitate Proof of Concept Trials to enable prevention of AD (build registries, longitudinal natural history study to qualify and validate biomarkers, pharmacological intervention trial modelled on SPY-2) Blood-based Biomarker assays for personalized tumor therapy: the value of circulating tumor cells, tumor DNA, and mirna Establishment and clinical validation of methods capturing CRCs in different indications to facilitate development of (companion) diagnostics and (personalized) treatments 3

Zoonoses Anticipation and Preparedness Initiative As new outbreaks could spread over large territories in just a few months, the program aim at increasing speed of development of the control tools (less than 6 months after occurrence of new zoonosis) Identification and clinical validation of new targets Therapeutic areas/scope under discussion European clinical research network for children and adolescents with diabetes and endocrine disorders To develop the paediatric research infrastructure across the EU within the field of diabetes and endocrinology; to develop and implement Paediatric Investigational Plans; design strategies for medicines development therapeutic areas under discussion Consistency of approach for vaccines batch release to make use of technology innovation in the areas of analytical methods, in vitro models demonstrating functionality of immune responses, and bioinformatics, and then translate these new technologies to a set of consistency tests that will allow improved monitoring of vaccine quality during production and final formulation Developing Drug-Drug Combinations to advance basic research and science on drug-drug combinations enabling a faster, more efficient, and less expensive development process ; to advance the understanding of the underlying health economic aspects 4

ND4BB: mixed infections, gram-negative/positive, 1-2 clinical studies ND4BB: clinical study, paediatric 5